Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration

Avery, Robert L.; Pieramici, Dante J.; Rabena, Melvin D.; Castellarin, Alessandro; Nasir, Maʼan; Giust, Matthew J.

doi:10.1016/j.ophtha.2005.11.019

Cited by 1,099 publications

(746 citation statements)

References 23 publications

Supporting

Mentioning

689

Contrasting

Unclassified

Order By: Relevance

“…Although similar results have been documented in previous reports at 3 months, 8,9 here we demonstrate that visual improvement can last 9 months with continued treatment. Indeed, approximately 10% of patients required only one injection for stabilisation of VA lasting 6 months.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results

Cleary

Jungkim

Ravikumar

et al. 2007

Eye

View full text Add to dashboard Cite

Purpose To evaluate 6-and 9-month follow-up data including the effect on vision and anatomic outcome in patients treated with intravitreal bevacizumab for neovascular age-related macular degeneration (AMD). Study design Interventional consecutive retrospective case series. Patients received intravitreal bevacizumab for the treatment of neovascular AMD including choroidal neovascular membranes, pigment epithelial detachment, and macular haemorrhage. Ophthalmic evaluation included log MAR or Snellen acuity, ophthalmic examination, optical coherence tomography, and fluorescein angiography. Repeat injections were given in the presence of persistent leakage or retinal oedema. Change in vision and foveal thickness from baseline was evaluated using the paired Student's t-test.

show abstract

Section: Discussionsupporting

confidence: 93%

“…8,9 Moreover, even patients with a baseline VA p1.0 on the log MAR scale had a substantial treatment benefit.…”

Section: Discussionmentioning

confidence: 98%

Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results

Cleary

Jungkim

Ravikumar

et al. 2007

Eye

View full text Add to dashboard Cite

show abstract

“…The most commonly used agents, bevacizumab and ranibizumab, reduce exudative fluid and have been shown to improve best-corrected visual acuity (BCVA) in eyes with nAMD compared with controls. [2][3][4] Aflibercept is a new anti-VEGF agent, which is a recombinant fusion protein consisting of key human VEGF receptor 1 and 2 extracellular domains (VEGFR1 and VEGFR2) fused to the Fc domain of human IgG1. 5,6 This protein binds VEGF-A, VEGF-B, and placental growth factor (PlGF), thus inhibiting the binding and the activation of VEGF receptors.…”

Section: Introductionmentioning

confidence: 99%

Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy

Ricci

Parravano

Regine

et al. 2016

Eye

View full text Add to dashboard Cite

Purpose To evaluate the effects of aflibercept administered according to a pro re nata (PRN) or Fixed Regimen to patients with neovascular AMD and persistent intraretinal/ subretinal fluid (IRF/SRF) despite three consecutive ranibizumab injections. Methods Patients were switched to aflibercept injection (IVA) administered according to a PRN or to a fixed regimen for 1 year in two different retina centers. At baseline each patient underwent a complete ophthalmologic evaluation, including bestcorrected visual acuity assessment (BCVA ETDRS chart), fluorescein, and indocyanine green angiography and OCT. Results Each group included 36 eyes. After 1 year the PRN group showed BCVA stabilization (63 vs 60 letters, P = 0.33), whereas fixed regimen group showed significant BCVA improvement (68 vs 71, P = 0.008). The median central retinal thickness decreased by 94 μm in the PRN (P = 0.002) and by 148 μm in the fixed regimen group (P ≤ 0.001). Complete IRF/SRF reabsorption was found in 58% of eyes in the PRN and in 42% of eyes in the fixed regimen group. At 1-year visit, the percentage of eyes with pigment epithelium detachment did not significantly decrease, but a height reduction was recorded in both groups. The median number of IVA was 3.5 in the PRN and 7 in the fixed regimen group. Conclusion The switch to aflibercept with both treatment strategies enabled improvement in morphological parameters and stabilization of visual acuity. BCVA improvement and reduction in vision loss with reduction in retinal thickness, fluid and PED height was achieved with the fixed regimen in previously treated nAMD after 1 year.

show abstract

“…[1][2][3][4][5] The purpose of this study is to describe short-term visual and anatomic outcomes following IVB for macular oedema (ME) due to branch retinal vein occlusion (BRVO).…”

Section: Introductionmentioning

confidence: 99%

Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion

Gündüz

Bakri

2008

Eye

View full text Add to dashboard Cite

Purpose To report short-term results of intravitreal bevacizumab (IVB) injection for macular oedema (ME) associated with branch retinal vein occlusion (BRVO). Methods Retrospective interventional case series of 12 eyes of 12 consecutive patients. IVB injections (1.25 mg/0.05 ml) were given as needed based on the presence of ME on optical coherence tomography. Changes in Snellen visual acuity (VA) and central macular thickness (CMT) were analysed using the Student's paired t-test. Results At a mean follow-up of 9.8 months (range: 6-17 months), the mean number of IVB injections given was 4 (range: 1-6). No ocular or systemic side effects were noted. The differences in logMAR VA between baseline and 1 month, between baseline and 6 months, and between baseline and final follow-up were statistically significant (Po0.05). The differences in CMT between baseline and 1 month, baseline and 6 months, and between baseline and final follow-up were also statistically significant (Po0.05). Conclusion Short-term results indicate that IVB is useful in decreasing ME and improving VA in eyes with BRVO.

show abstract

Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration

Cited by 1,099 publications

References 23 publications

Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results

Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results

Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy

Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion

Contact Info

Product

Resources

About